Community post

Armata Pharmaceuticals has completed enrollment of its Phase 2 Tailwind study, which will evaluate efficacy of inhaled AP-PA02 in non-CF bronchiectasis patients with chronic pulmonary P. aeruginosa infection. Data anticipated in the second half of 2024.